Complete SILO Stock Valuation Analysis
Comprehensive intrinsic value analysis using 2 different methodologies
SILO DCF Analysis
SILO (Silo Pharma, Inc.) discounted cash flow analysis with multiple scenarios, growth assumptions, and terminal value calculations
Financial Projections
| Metrics | 2022 (Historical) | 2023 (Historical) | 2024 (Historical) | 2025 (Projected) | 2026 (Projected) | 2027 (Projected) | 2028 (Projected) | 2029 (Projected) |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72.1K | $72.1K | $72.1K | $77.6K | $83.0K | $88.1K | $93.0K | $97.7K |
| Revenue Growth % | - | 0.0% | 0.0% | 7.6% | 6.9% | 6.2% | 5.6% | 5.0% |
| EBIT | $-3.6M | $-3.9M | $-4.7M | $3.9K | $4.1K | $4.4K | $4.7K | $4.9K |
| EBIT Margin % | -5059.0% | -5347.4% | -6526.4% | 5.0% | 5.0% | 5.0% | 5.0% | 5.0% |
| Tax Rate % | 25.0% | 25.0% | 25.0% | 20.1% | 20.6% | 21.1% | 21.6% | 22.1% |
| NOPAT | $-2.7M | $-2.9M | $-3.5M | $3.1K | $3.3K | $3.5K | $3.6K | $3.8K |
| NOPAT Margin % | -3794.3% | -4010.6% | -4894.8% | 4.0% | 4.0% | 3.9% | 3.9% | 3.9% |
| Capex | $0 | $2 | $0 | $776 | $830 | $881 | $930 | $977 |
| Capex / Revenue % | 0.0% | 0.0% | 0.0% | 1.0% | 1.0% | 1.0% | 1.0% | 1.0% |
| Depreciation | $0 | $0 | $6.2K | $2.2K | $2.4K | $2.5K | $2.7K | $2.8K |
| D&A / Revenue % | 0.0% | 0.0% | 8.6% | 2.9% | 2.9% | 2.9% | 2.9% | 2.9% |
| Change in NWC | $1.2M | $-4.2M | $-1.5M | $0 | $0 | $0 | $0 | $0 |
| NWC Change / Revenue % | 1696.8% | -5866.9% | -2011.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Unlevered FCF | $-4.0M | $1.3M | $-2.1M | $4.5K | $4.8K | $5.1K | $5.4K | $5.6K |
| UFCF % Chg. | - | 133.8% | -254.9% | 100.2% | 6.4% | 5.8% | 5.1% | 4.6% |
| FCF / Revenue % | -5491.1% | 1856.4% | -2875.1% | 5.9% | 5.8% | 5.8% | 5.8% | 5.8% |
| Discount Factor | - | - | - | 0.902 | 0.814 | 0.734 | 0.663 | 0.598 |
| Present Value of FCF | - | - | - | $4.1K | $3.9K | $3.8K | $3.6K | $3.4K |
| Sum of PV of UFCF | - | - | - | $4.1K | $8.0K | $11.8K | $15.4K | $18.7K |
WACC Calculation
Weighted Average Cost of Capital used for discounting cash flows.
| WACC Calculation | Value |
|---|---|
| Cost of Debt | 6.8% |
| Tax Rate | 20.1% |
| After Tax Cost of Debt | 5.4% |
| Risk Free Rate | 4.26% |
| Market Risk Premium | 4.3% |
| Beta | 1.52 |
| Cost of Equity | 10.8% |
| Total Debt | $0 |
| Market Cap | $4.5M |
| Total Capital | $4.5M |
| Debt Weighting | 0.0% |
| Equity Weighting | 100.0% |
| WACC | 10.8% |
Terminal Value
Choose between perpetuity growth or exit multiple methods.
| Terminal Value Calculation | Value |
|---|---|
| Terminal Growth Rate | 2.5% |
| Final Year FCF | $5.6K |
| Terminal Value | $69.1K |
| PV of Terminal Value | $41.3K |
| Cumulative PV of UFCF | $18.7K |
| Net Debt | $-3.9M |
| Equity Value | $4.0M |
| Shares Outstanding | 3.7M |
| Implied Share Price | $1 |
| Current Share Price | $1 |
| Implied Upside/(Downside) | +71.7% |
Valuation Summary
$1.08
Implied Price
$0.63
Current Price
+71.7%
Upside/Downside
10.8%
WACC
SILO Peer Valuation Analysis
Relative valuation based on comparable company trading multiples
Peer Valuation Analysis
Fair Value Range Analysis
Based on median multiples from 6 peer companies in Healthcare
P/E Ratio
$-0.01
-101.8%
Peer Median: 0.0x
EV/EBITDA
$0.00
-100.0%
Peer Median: 0.0x
P/S Ratio
$0.02
-97.1%
Peer Median: 1.8x
Interpretation: Each multiple provides a different perspective on fair value. Consider which multiple is most relevant for SILO's business model and current situation.
Multiple Comparison
| Multiple | SILO Current | Peer Median | Peer Average | Premium/Discount | Assessment |
|---|---|---|---|---|---|
| P/E Ratio | -0.6x | 0.0x | 0.0x | -5745.6% | Undervalued |
| EV/EBITDA | Infinityx | 0.0x | 0.0x | Infinity% | Overvalued |
| P/S Ratio | 62.7x | 1.8x | 1.6x | 3326.0% | Overvalued |
Peer Companies
Click any company to view their valuation
| Company | Market Cap | P/E Ratio | EV/EBITDA | P/S Ratio |
|---|---|---|---|---|
| $0.00B | 0.0x | 0.0x | 1.8x | |
| $0.01B | 0.0x | 0.0x | 0.0x | |
| $0.00B | 0.0x | 0.0x | 31.1x | |
| $0.00B | 0.0x | 0.0x | 1.4x | |
| $0.00B | 0.0x | 0.0x | 62.7x | |
| $0.00B | 0.0x | 0.0x | 0.0x |